Implanted Haemodynamic Monitoring promising Tool for PH Management in adults with sRVs

Written By :  Dr Riya Dave
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-11-13 04:45 GMT   |   Update On 2023-11-13 08:53 GMT

Pulmonary hypertension (PH) poses a common complication for individuals with complete dextro-transposition of the great arteries (D-TGA) after atrial switch (AS) and congenitally corrected TGA (ccTGA) who exhibit subaortic right ventricles (sRVs). This study was published in the Heart journal by Marshall V. and colleagues. A recent retrospective study has explored the utility of...

Login or Register to read the full article

Pulmonary hypertension (PH) poses a common complication for individuals with complete dextro-transposition of the great arteries (D-TGA) after atrial switch (AS) and congenitally corrected TGA (ccTGA) who exhibit subaortic right ventricles (sRVs). This study was published in the Heart journal by Marshall V. and colleagues.

A recent retrospective study has explored the utility of implantable invasive hemodynamic monitoring (IHM) in this patient population, revealing novel applications and its potential impact on heart failure hospitalisation (HFH) and device-related complications.

  • Patient Demographics:

The study involved 18 patients with sRVs.

Median age: 43 years (range: 30-54).

Diagnosis: 16 with D-TGA/AS, 2 with ccTGA.

  • IHM Applications:

Medical Therapy Titration: IHM played a crucial role in adjusting medical therapy for patients.

Post-Ventricular Assist Device (VAD) Management: IHM facilitated medical management in individuals with transplant-limiting PH post-VAD.

Serial Monitoring for Heart Transplant Referral: IHM enabled the continuous monitoring of pulmonary artery pressures, potentially eliminating the need for repeat catheterizations to identify optimal heart transplant referral times.

  • Clinical Impact:

In a median follow-up of 23 months, the rate of HFHs per year remained similar to the period before IHM implementation.

HFHs/year pre-IHM: Median 0 (IQR 0-1.0).

HFHs/year post-IHM: Median 0 (IQR 0-0.8) (p=0.984).

  • Device-Related Complications:

Device migration occurred in one patient, but without long-term consequences.

The study underscores the diverse applications of IHM in patients with sRVs, offering valuable insights into managing PH in this complex population. IHM demonstrated effectiveness in medical therapy titration, post-VAD management, and serial monitoring for heart transplant referral. Notably, the overall impact on HFH rates was minimal, emphasizing the potential of IHM in optimizing patient care without significantly altering hospitalization outcomes. The occurrence of a single device-related complication, with no lasting effects, highlights the safety profile of IHM in this context.

Reference:

Marshall, W. H., V., Mah, M. L., DeSalvo, J., Rajpal, S., Lastinger, L. T., Salavitabar, A., Armstrong, A. K., Berman, D., Lampert, B., Wright, L. K., Hickey, J., Metzger, R., Nandi, D., Gajarski, R., & Daniels, C. J. Novel uses for implanted haemodynamic monitoring in adults with subaortic right ventricles. Heart (British Cardiac Society), heartjnl-2023-323206. https://doi.org/10.1136/heartjnl-2023-323206 

Tags:    
Article Source : Heart journal

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News